Navidea's Lymphoseek meets clinical trial goals for new indication

10/11/2013 | (free registration)

Navidea Biopharmaceuticals announced that a Phase III trial of Lymphoseek, its technetium Tc-99m tilmanocept imaging agent, met study goals in terms of sensitivity, negative predictive value and overall accuracy of nonsentinel lymph node diagnosis in assessment of cancer in the head or mouth. The company may submit a supplemental new drug application by the end of the year based on the positive study results.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC